Polyrizon Ltd. announced today the filing of a divisional patent application with the Israel Patent Office for its Trap & Target (T&T) platform technology. This application is specifically focused on protecting the company’s advanced intranasal drug delivery system.
The T&T platform is designed to enhance the effectiveness of medications by increasing their residence time and ensuring close contact with mucosal tissues. This novel approach aims to improve the bioavailability of active pharmaceutical ingredients for both local and systemic drug delivery.
Tomer Izraeli, CEO of Polyrizon, stated that this filing is another important step in strengthening the company's global intellectual property portfolio. The T&T platform has potential applications for conditions such as allergic rhinitis, epileptic seizures, and opioid overdose.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.